Mach7 Technologies (ASX:M7T) signed a five-year subscription license agreement with not-for-profit health system UnityPoint Health for its new Flamingo Architecture products, according to a Wednesday filing with the Australian bourse.

The subscription license is expected to initially contribute around AU$600,000 to the annual recurring revenue, growing up to AU$1 million, based on an increase in usage from a minimum of 1.5 million studies per year to an anticipated 3 million studies per year, the filing said.

Mach7 Technologies shares rose 3% in afternoon trade on Wednesday.